CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia
"CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Olga Frankfurt
- Courtney Denton Dinardo (ORCID: https://orcid.org/0000-0001-9003-0390)
- Deepa Jeyakumar (ORCID: https://orcid.org/0000-0002-8822-1814)
- Jason G. Harb
- Jiuhong Zha (ORCID: https://orcid.org/0000-0003-2344-474X)
- Olatoyosi M. Odenike (ORCID: https://orcid.org/0000-0002-4027-4124)
- Brian A. Jonas (ORCID: https://orcid.org/0000-0002-4921-5809)
- Anjali S. Advani (ORCID: https://orcid.org/0000-0003-0015-5902)
- Raya Mawad
- Minh H. Dinh
Institutions
- Northwestern University (US)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Irvine (US)
- AbbVie (United States) (US)
- University of Chicago (US)
- Newport (United States) (US)
- Swedish Medical Center (US)
- University of California, Davis (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7122
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00